产后溶血性尿毒症3例病例分析及文献复习
Analysis of 3 Cases of Postpartum Hemolytic Uremia and Review of Literature
DOI: 10.12677/ACM.2023.13102170, PDF,   
作者: 王枭梦, 刘俐君, 王夙斐, 易村犍*:长江大学附属第一医院妇产科,湖北 荆州
关键词: 产后溶血尿毒症血栓性微血管病Postpartum Hemolytic Uremia Thrombotic Cardiomyopathy
摘要: 目的:总结产后溶血性尿毒症的高危因素、临床表现、辅助检查、鉴别诊断及治疗方法,提高对本病的认识,达到早期诊断、早期干预,降低患者死亡率,改善预后。方法:回顾性分析就诊于荆州市第一人民医院的3例产后溶血性尿毒症的患者并复习相关文献。结果:3例患者均有发生产后溶血性尿毒症的高危因素,并于产后24~48 h出现无尿/少尿,实验室检查提示溶血性贫血或消耗性凝血病、血小板减少及肾功能损害。予以血浆置换、血液透析、肾脏替代疗法、激素等对症治疗后,2例患者肾功能持续好转后出院,1例患者死亡。结论:产后溶血性尿毒症临床少见,症状无特异性,早期诊断困难,因此当患者合并产后溶血性尿毒症的高危因素时均应警惕产后溶血性尿毒症的发生。
Abstract: Objective: To summarize the high risk factors, clinical manifestations, auxiliary examination, dif-ferential diagnosis and treatment of postpartum hemolytic uremia, so as to improve the under-standing of this disease, achieve early diagnosis and intervention, reduce the mortality of patients and improve the prognosis. Methods: 3 cases of postpartum hemolytic uremia treated in Jingzhou First People’s Hospital were analyzed retrospectively and related literatures were reviewed. Re-sults: All the three patients had high risk factors for postpartum hemolytic uremia, and anuria/ ol-igarch occurred from 24 h to 48 h after delivery. Laboratory examination indicated hemolytic ane-mia or wasting coagulation disease, thrombolytic and renal function impairment. After symptomat-ic treatment such as plasma exchange, dialysis, kidney replacement therapy and hormone, 2 pa-tients were discharged from hospital after continuous improvement of renal function, and 1 patient died. Conclusion: Postpartum hemolytic uremia is rare in clinic, the symptoms are not specific, and the early diagnosis is difficult. Therefore, the occurrence of postpartum hemolytic uremia should be vigilant when patients are combined with high-risk factors of postpartum hemolytic uremia.
文章引用:王枭梦, 刘俐君, 王夙斐, 易村犍. 产后溶血性尿毒症3例病例分析及文献复习[J]. 临床医学进展, 2023, 13(10): 15517-15522. https://doi.org/10.12677/ACM.2023.13102170

参考文献

[1] Raina, R., Krishnappa, V., Blaha, T., et al. (2019) Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiolo-gy, Diagnosis, and Treatment. Therapeutic Apheresis and Dialysis, 23, 4-21. [Google Scholar] [CrossRef] [PubMed]
[2] Song, D., Yu, X.-J., Wang, F.-M., et al. (2015) Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement. American Journal of Reproductive Immunology, 74, 345-356. [Google Scholar] [CrossRef] [PubMed]
[3] 彭雪, 吴钊, 彭冰. 产后溶血性尿毒症综合征诊治进展[J]. 实用妇产科杂志, 2017, 33(8): 579-582.
[4] Yoshida, Y., Kato, H., Ikeda, Y. and Nangaku, M. (2019) Pathogenesis of Atypical Hemolytic Uremic Syndrome. Journal of Atherosclerosis and Thrombosis, 26, 99-110. [Google Scholar] [CrossRef
[5] McCullough, J.W., Renner, B. and Thur-man, J.M. (2013) The Role of the Complement System in Acute Kidney Injury. Seminars in Nephrology, 33, 543-556. [Google Scholar] [CrossRef] [PubMed]
[6] 林矜, 余自华. 补体旁路途径失调非典型溶血尿毒综合征的诊断和治疗[J]. 罕少疾病杂志, 2022, 29(5): 1-5.
[7] 王晨虹. 产后溶血性尿毒症综合征[J]. 中华产科急救电子杂志, 2014, 3(3): 190-192.
[8] Iannuzzi, M., Siconolfi, P., D’Angelillo, A, et al. (2006) A Post-Partum Hemo-lytic-Uremic-Like-Syndrome in a Patient with Pre-Eclampsia: Description of a Clinical Case. Transfusion and Apheresis Science, 34, 11-14. [Google Scholar] [CrossRef] [PubMed]
[9] Rieger, M., Mannucci, P.M., Kremer Hovinga, J.A, et al. (2005) ADAMTS13 Autoantibodies in Patients with Thrombotic Microangiopathies and Other Immunomediated Diseases. Blood, 106, 1262-1267. [Google Scholar] [CrossRef] [PubMed]
[10] DeYoung, V., Singh, K. and Kretz, C.A. (2022) Mechanisms of ADAMTS13 Regulation. Journal of Thrombosis and Haemostasis, 20, 2722-2732. [Google Scholar] [CrossRef] [PubMed]
[11] Burwick, R.M., Moyle, K., Java, A. and Gupta, M. (2021) Differentiating Hemolysis, Elevated Liver Enzymes, and Low Platelet Count Syndrome and Atypical Hemolytic Uremic Syndrome in the Postpartum Period. Hypertension, 78, 760-768. [Google Scholar] [CrossRef
[12] 李雪艳, 刘晓巍. 妊娠期急性脂肪肝的研究进展[J]. 中国妇产科临床杂志, 2021, 22(5): 559-560. [Google Scholar] [CrossRef
[13] Loirat, C., Fakhouri, F., Ariceta, G., et al. (2016) An International Consensus Approach to the Management of Atypical Hemolytic Uremic Syndrome in Children. Pediatric Nephrology, 31, 15-39. [Google Scholar] [CrossRef] [PubMed]
[14] Legendre, C.M., Licht, C., Muus, P., et al. (2013) Terminal Com-plement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome. The New England Journal of Medicine, 368, 2169-2181. [Google Scholar] [CrossRef
[15] Åkesson, A., Martin, M., Blom, A.M., et al. (2021) Clinical Char-acterization and Identification of Rare Genetic Variants in Atypical Hemolytic Uremic Syndrome: A Swedish Retrospec-tive Observational Study. Therapeutic Apheresis and Dialysis, 25, 988-1000. [Google Scholar] [CrossRef] [PubMed]
[16] Tanaka, K., Adams, B., Aris, A.M., et al. (2021) The Long-Acting C5 Inhibitor, Ravulizumab, Is Efficacious and Safe in Pediatric Patients with Atypical Hemolytic Uremic Syndrome Pre-viously Treated with Eculizumab. Pediatric Nephrology, 36, 889-898. [Google Scholar] [CrossRef] [PubMed]
[17] 戴艺萍, 阮一平, 洪富源. 非典型溶血性尿毒症治疗的研究进展[J]. 罕少疾病杂志, 2022, 29(7): 1-4.